Jpmorgan Chase & CO Enanta Pharmaceuticals Inc Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 158,546 shares of ENTA stock, worth $1.76 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
158,546
Previous 138,047
14.85%
Holding current value
$1.76 Million
Previous $2.41 Million
14.69%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ENTA
# of Institutions
102Shares Held
21MCall Options Held
10.4KPut Options Held
2.3K-
Farallon Capital Management LLC San Francisco, CA2.1MShares$23.3 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.93MShares$21.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.85MShares$20.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.46MShares$16.2 Million0.0% of portfolio
-
Krensavage Asset Management, LLC New York, NY1.25MShares$13.9 Million7.45% of portfolio
About ENANTA PHARMACEUTICALS INC
- Ticker ENTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,724,900
- Market Cap $230M
- Description
- Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...